dc.contributor.author | Solli, Kristin Klemmetsby | |
dc.contributor.author | Kunøe, Nikolaj | |
dc.contributor.author | Latif, Zill-E-Huma | |
dc.contributor.author | Haase, Kamni Sharma | |
dc.contributor.author | Opheim, Arild | |
dc.contributor.author | Krajci, Peter | |
dc.contributor.author | Gaulen, Zhanna | |
dc.contributor.author | Saltyte Benth, Jurate | |
dc.contributor.author | Tanum, Lars Håkon Reiestad | |
dc.date.accessioned | 2020-03-16T09:45:30Z | |
dc.date.accessioned | 2020-03-28T12:13:43Z | |
dc.date.available | 2020-03-16T09:45:30Z | |
dc.date.available | 2020-03-28T12:13:43Z | |
dc.date.issued | 2019-07-19 | |
dc.identifier.citation | Solli KK, Kunøe N, Latif HL, Haase K, Opheim A, Krajci P, Gaulen Z, Saltyte Benth J, Tanum L. Availability of extended-release naltrexone may increase the number of opioid-dependent individuals in treatment: Extension of a randomized clinical trial. European Addiction Research. 2019;25(6):1-7 | en |
dc.identifier.issn | 1022-6877 | |
dc.identifier.issn | 1022-6877 | |
dc.identifier.issn | 1421-9891 | |
dc.identifier.uri | https://hdl.handle.net/10642/8333 | |
dc.description.abstract | Background and objective: Opioid maintenance treatment (OMT) is highly available in Norway, but only 50% of opioid-dependent individuals are enrolled in such programs. This study was aimed at examining if availability of extended-release naltrexone (XR-NTX) could attract individuals who for different reasons were not enrolled in an OMT program. Methods: In a Norwegian clinical study, n = 117 opioid-dependent adults volunteered to receive XR-NTX in a 9-month period, as an extension of a previous randomized clinical trial. Results: Before study inclusion, 40.2% (n = 47) of the study participants were not enrolled in OMT while the remainder were recruited from OMT. Participants not enrolled in OMT displayed more ongoing severe addiction-related problems such as heroin use (p = 0.002), but displayed a higher retention in treatment in the 9-month extension study (p = 0.048 for log-rank test) than participants enrolled in OMT. Conclusion: Availability of XR-NTX attracted opioid-dependent individuals not previously enrolled in OMT. While OMT may be perceived as a burden with regard to daily intake and control measures, one-monthly injections with XR-NTX may be perceived favourable, offering more freedom to the patients, not having addictive properties, and potentially reducing heroin craving. We suggest that an introduction of XR-NTX in Europe may increase the number of opioid-dependent individuals in treatment. | en |
dc.description.sponsorship | This work was supported by unrestricted grants from the Research Council of Norway (Grant # 204725-3) and the Western Norway Regional Health Authority. Financial support was also received from the Norwegian Centre for Addiction Research, University of Oslo, and from Akershus University Hospital. Extended-release naltrexone (Vivitrol®) was provided to this investigator-initiated study by the manufacturer Alkermes. Inc. | en |
dc.language.iso | en | en |
dc.publisher | Karger Publishers | en |
dc.relation.ispartofseries | European Addiction Research;2019, Vol. 25, No. 6 | |
dc.rights | This is the peer-reviewed but unedited manuscript version of the following article: Solli K, K, Kunoe N, Latif Z, -E, -H, Sharma-Haase K, Opheim A, Krajci P,
Gaulen Z, Šaltytė Benth J, Tanum L: Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial. Eur Addict Res 2019;25:303-309. DOI: https://dx.doi.org/10.1159/000501931
The final, published version is available at https://www.karger.com/Article/Abstract/501 | en |
dc.subject | Naltrexone | en |
dc.subject | Extended release naltrexone | en |
dc.subject | Opioid dependency | en |
dc.subject | Maintenance treatment programs | en |
dc.subject | Opioid dependency treatments | en |
dc.subject | Opioid maintenance treatments | en |
dc.title | Availability of extended-release naltrexone may increase the number of opioid-dependent individuals in treatment: Extension of a randomized clinical trial | en |
dc.type | Journal article | en |
dc.type | Peer reviewed | en |
dc.date.updated | 2020-03-16T09:45:30Z | |
dc.description.version | acceptedVersion | en |
dc.identifier.doi | https://dx.doi.org/10.1159/000501931 | |
dc.identifier.cristin | 1713146 | |
dc.source.journal | European Addiction Research | |